

Multi-Stakeholder Partnership to Eliminate Hepatitis C Virus (HCV) in 47 English Prisons

Philip J. F. Troke Ph.D.
UK & Ireland Medical Director for Liver & COVID-19
Gilead Sciences Ltd.

Troke P¹, Jones A¹, Cox S², Cheetham R³, Halford R², Brew I³

¹ Gilead Sciences Ltd. London, UK. ² Hepatitis C Trust, London, UK. ³ Practice Plus Group, Reading, UK.

Disclaimer

- The regional blood-borne virus (BBV) nurse team within Practice Plus Group (PPG) and National Prison Partnership HITT Manager within the Hepatitis C Trust are fully funded by Gilead.
- Gilead plays an active role in the design and execution of the activities that form this Prison HCV Elimination Program.
- Selection of DAA treatment regimen is determined by the treating clinician following the national rate card and with patient input; Gilead staff have no influence over regimen selection.
- The presenter is employed by Gilead Sciences Ltd.

Background


- National Health Service England (NHSE) plans to eliminate Hepatitis C in England by 2025¹
 - To support this, their HCV treatments tender was redesigned to contractually engage the pharma companies in delivering HCV screening and linkage to care activities
- Prisons in England have an estimated HCV antibody prevalence of ~7%²
- Many prison residents don't routinely engage with healthcare outside prison
- Prison healthcare provision is contracted by the NHS to third party providers, enabling partnerships between pharma and these providers to deliver service improvements
 - Practice Plus Group delivers healthcare for 47 prisons in England
 - In January 2019, only 25% of new admissions to PPG-healthcare prisons were tested for HCV

¹https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/898221/HCV_in_England_2020_report.pdf

²Kirwan P, Evans B, Brant L. Hepatitis C and B testing in English prisons is low but increasing. J Public Health (Oxf). 2011;33(2):197-204.


Method

- In May 2019 a formal partnership between **Gilead**, **Practice Plus Group (PPG)** and the **Hepatitis C Trust (HCT)** was formed to eliminate HCV within the PPG-healthcare prison estate
 - Each organisation brought their own expertise to focus on a single challenge
- The Partnership focuses on:
 - Improving knowledge, and reducing stigma, of HCV amongst prison residents and officers
 - Improving reception screening for BBVs
 - HCV care pathway development for those diagnosed
 - Implementing HITTs to ‘test-and-treat’ those already incarcerated
 - Achieving HCV micro-elimination within each prison




Results across the 47 prisons with PPG-healthcare

- **85,267** HCV antibody tests were performed in total from 1st May 2019 through 31st July 2021
- **1,757 residents** were newly recorded as **HCV RNA+**
- **1,695 residents** were initiated on **DAA** therapy whilst resident
- As of 1st September 2021 **17 prisons** have **achieved NHSE micro-elimination** status
 - 95% testing of residents within 12 months and at least 90% of RNA positive patients commenced on treatment



Impact of PPG-prison HCV partnership on progress towards HCV elimination



Summary

THE WHY

- Hepatitis C infection disproportionately impacts disadvantaged communities who often have poorer access to healthcare
- Prison provides an environment in which residents can be tested for BBVs and supported onto, and through, treatment

THE HOW

- Partnership between public and private healthcare service providers, a patient organization and pharma

THE ACHIEVEMENTS

- Across 47 prisons:
 - Increase in HCV testing upon prison entry from 23% to 87% with over 85,000 tests performed
 - 1,700 residents treated for HCV
 - Reduction in HCV infection prevalence to 1.5%